NCT02578914View on ClinicalTrials.gov

A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Allergic ConjunctivitisSeasonal Allergies
Interventions
DRUG

NS2 Ophthalmic Drops (0.5%)

DRUG

NS2 Ophthalmic Drops Vehicle (0.0%)

Trial Locations (1)

L4W 1A4

Inflamax Research Inc., Mississauga

Sponsors
All Listed Sponsors
lead

Aldeyra Therapeutics, Inc.

INDUSTRY

NCT02578914 - A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis | Biotech Hunter | Biotech Hunter